ClinicalTrials.gg
TerminatedNCT03943147Updated Oct 17, 2022Results posted

An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

A Phase 2 interventional study of BMS-986165 and Placebo in Lupus Nephritis, sponsored by Bristol-Myers Squibb. Terminated at 100 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-10-17.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was terminated
Insufficient enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Enrollment
73rd of 100
16 · median 50
Started
2019
with 2 others
Phase 2
34 of 114
7 open now
Registered
45th of 114
by date
Lead sponsor
3 of 114
Bristol-Myers Squibb

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 73rd largest by enrollment of the 100 interventional ones that give a count, is one of 3 that started in 2019, is one of 34 in phase 2, and was the 45th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of BMS-986165 compared with placebo with regard to measures of kidney function in participants with lupus nephritis (LN).

03

Conditions studied

  • Lupus Nephritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Meets the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria for Systemic Lupus Erythematosus (SLE)
  • Renal confirming a histologic diagnosis of active Lupus Nephritis (LN) International Scociety of Nephrology/Renal Pathology Society (ISN/RPS) Classes III, IV-S, or IV-G; or Class V
  • Urine protein:creatinine ratio (UPCR) ≥1.5 mg/mg or UPCR ≥1 mg/mg assessed with a 24-hour urine specimen

Exclusion criteria

Exclusion Criteria:

  • Pure ISN/RPS Class V membranous LN
  • Screening estimated ≤30 mL/min/1.73 m\^2
  • Dialysis within 12 months before screening or plans for dialysis within 6 months after enrollment in the study
  • End-stage renal disease

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    BMS-986165 Dose 1

    Specified Dose on Specified Days

    Drug: BMS-986165 · Drug: Mycophenolate Mofetil

  • Experimental
    BMS-986165 Dose 2

    Specified Dose on Specified Days

    Drug: BMS-986165 · Drug: Mycophenolate Mofetil

  • Placebo comparator
    Placebo for BMS-986165

    Specified Dose on Specified Days

    Drug: Placebo · Drug: Mycophenolate Mofetil

  • Experimental
    Mycophenolate Mofetil (MMF)

    Specified Dose on Specified Days

    Drug: Mycophenolate Mofetil

Interventions

06

What researchers measure

Primary outcomes

  1. The Number of Participants Experiencing Averse Events in the Blinded Treatment Period (Part B)

    An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Data collected from the week 12 visit in Part A will be used for baseline values in Part B.

    Time frame: From baseline up to 52 weeks after first dose in Part B

  2. The Number of Participants With Clinically Significant ECG Abnormalities in the Blinded Treatment Period (Part B)

    The number of participants with clinically significant abnormalities in electrocardiograms (ECGs) parameters. The following ECG parameters will be measured: HR, PR-interval, QRS-duration, QT-interval, QTc-interval. A single 12-lead ECG will be recorded after the participant has been supine for at least 5 minutes. Data collected from the week 12 visit in Part A will be used for baseline values in Part B.

    Time frame: From baseline up to 52 weeks after first dose in Part B

  3. The Percent Change in Vital Sign Measurements in the Blinded Treatment Period (Part B)

    The percent change from baseline in Vital sign measurements including: blood pressure, heart rate, respiratory rate, and temperature. Blood pressure and heart rate are measured after the participant has been resting quietly for at least 5 minutes. Data collected from the week 12 visit in Part A will be used for baseline values in Part B.

    Time frame: From baseline up to 52 weeks after first dose in Part B

  4. The Number of Participants With Abnormal Laboratory Parameters of Clinical Significance in the Blinded Treatment Period (Part B)

    The number of participants with abnormal laboratory parameters (Chemistry, hematology, coagulation, immunohematology) that have been considered clinically significant. Clinically relevant laboratory results are determined by the investigator. Data collected from the week 12 visit in Part A will be used for baseline values in Part B.

    Time frame: From baseline up to 52 weeks after first dose in Part B

  5. Percent Change From Baseline in 24-hour Urine Protein:Creatinine Ratio (UPCR) at Week 24 in the Blinded Treatment Period (Part B)

    The percent change from baseline in UPCR based on 24-hour urine collections. 24-hour urine specimens measure the levels of proteins and creatinine in urine and will be used for the UPCR at baseline (week 12) and week 24.

    Time frame: Week 24

Secondary outcomes

  1. The Number of Participants With Partial Renal Response (PRR) at Week 24 in the Blinded Treatment Period (Part B)

    The number of participants with partial renal response (PRR) defined as ≥ 50% reduction from baseline in 24-hour Urine Protein:Creatinine Ratio (UPCR). 24-hour urine specimens measure the levels of proteins and creatinine in urine and will be used for the UPCR at baseline (week 12) and week 24.

    Time frame: Week 24

  2. The Number of Participants With Partial Renal Response (PRR) at Week 52 in the Blinded Treatment Period (Part B)

    The number of participants with partial renal response (PRR) defined as ≥ 50% reduction from baseline in 24-hour Urine Protein:Creatinine Ratio (UPCR). 24-hour urine specimens measure the levels of proteins and creatinine in urine and will be used for the UPCR at baseline (week 12) and week 52.

    Time frame: Week 52

  3. The Number of Participants With Complete Renal Response (CRR) at Week 24 in the Blinded Treatment Period (Part B)

    The number of participants with complete renal response (CRR) defined as a 24-hour Urine Protein:Creatinine Ratio (UPCR) ≤ 0.5 mg/mg and an estimated glomerular filtration rate (eGFR) (using the MDRD equation) ≥ 60 mL/min or ≤ 20% decrease from baseline.

    Time frame: Week 24

  4. The Number of Participants With Complete Renal Response (CRR) at Week 52 in the Blinded Treatment Period (Part B)

    The number of participants with complete renal response (CRR) defined as a 24-hour Urine Protein:Creatinine Ratio (UPCR) ≤ 0.5 mg/mg and an estimated glomerular filtration rate (eGFR) (using the MDRD equation) ≥ 60 mL/min or ≤ 20% decrease from baseline.

    Time frame: Week 52

  5. The Number of Participants With Complete Renal Response (CRR) Plus Successful Corticosteroid Taper to ≤ 7.5 mg/Day at Week 24 in the Blinded Treatment Period (Part B)

    The number of participants with complete renal response (CRR) defined as a 24-hour Urine Protein:Creatinine Ratio (UPCR) ≤ 0.5 mg/mg and an estimated glomerular filtration rate (eGFR) (using the MDRD equation) ≥ 60 mL/min or ≤ 20% decrease from baseline who was also able to successfully taper corticosteroid use to ≤ 7.5 mg/day.

    Time frame: Week 24

  6. The Number of Participants With Complete Renal Response (CRR) Plus Successful Corticosteroid Taper to ≤ 7.5 mg/Day at Week 52 in the Blinded Treatment Period (Part B)

    The number of participants with complete renal response (CRR) defined as a 24-hour Urine Protein:Creatinine Ratio (UPCR) ≤ 0.5 mg/mg and an estimated glomerular filtration rate (eGFR) (using the MDRD equation) ≥ 60 mL/min or ≤ 20% decrease from baseline who was also able to successfully taper corticosteroid use to ≤ 7.5 mg/day.

    Time frame: Week 52

07

Results

Posted Oct 17, 2022
Limitations and caveats
Due to low enrollment, the Sponsor chose to terminate the study on 01-Jul-2021 and consequently there is limited data available from a single randomized participant. Due to lack of sufficient data, no formal statistical analyses of endpoints were conducted.

Participant flow

Open-Label MMF Run-in (Part A)
Participant flow — Open-Label MMF Run-in (Part A)
MilestoneOpen Label MMFOpen Label MMF + BMS-986165
Started160
Completed60
Not completed100
Withdrew: Other reasons40
Withdrew: Adverse event10
Withdrew: Non-compliance with study drug10
Withdrew: Protocol-specified withdrawal criterion met10
Withdrew: Study terminated by sponsor30
Blinded Treatment (Part B)
Participant flow — Blinded Treatment (Part B)
MilestoneOpen Label MMFOpen Label MMF + BMS-986165
Started51
Completed21
Not completed30
Withdrew: Study terminated by sponsor30

Outcome measures

PrimaryThe Number of Participants Experiencing Averse Events in the Blinded Treatment Period (Part B)

An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Data collected from the week 12 visit in Part A will be used for baseline values in Part B.

Time frame:
From baseline up to 52 weeks after first dose in Part B
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Averse Events in the Blinded Treatment Period (Part B)
ParticipantsOpen Label MMF + BMS-986165
The Number of Participants Experiencing Averse Events in the Blinded Treatment Period (Part B)1
PrimaryThe Number of Participants With Clinically Significant ECG Abnormalities in the Blinded Treatment Period (Part B)

The number of participants with clinically significant abnormalities in electrocardiograms (ECGs) parameters. The following ECG parameters will be measured: HR, PR-interval, QRS-duration, QT-interval, QTc-interval. A single 12-lead ECG will be recorded after the participant has been supine for at least 5 minutes. Data collected from the week 12 visit in Part A will be used for baseline values in Part B.

Time frame:
From baseline up to 52 weeks after first dose in Part B
Reported as:
Count of participants · Participants
The Number of Participants With Clinically Significant ECG Abnormalities in the Blinded Treatment Period (Part B)
ParticipantsOpen Label MMF + BMS-986165
The Number of Participants With Clinically Significant ECG Abnormalities in the Blinded Treatment Period (Part B)0
PrimaryThe Percent Change in Vital Sign Measurements in the Blinded Treatment Period (Part B)

The percent change from baseline in Vital sign measurements including: blood pressure, heart rate, respiratory rate, and temperature. Blood pressure and heart rate are measured after the participant has been resting quietly for at least 5 minutes. Data collected from the week 12 visit in Part A will be used for baseline values in Part B.

Time frame:
From baseline up to 52 weeks after first dose in Part B
Reported as:
Number · Percent change from baseline
The Percent Change in Vital Sign Measurements in the Blinded Treatment Period (Part B)
Percent change from baselineOpen Label MMF + BMS-986165
Diastolic Blood Pressure(mmHg)-3.45
Systolic Blood Pressure(mmHg5.22
Heart Rate(beats/min)16.87
Respiratory Rate(breaths/min)6.25
Temperature(C)-1.35
PrimaryThe Number of Participants With Abnormal Laboratory Parameters of Clinical Significance in the Blinded Treatment Period (Part B)

The number of participants with abnormal laboratory parameters (Chemistry, hematology, coagulation, immunohematology) that have been considered clinically significant. Clinically relevant laboratory results are determined by the investigator. Data collected from the week 12 visit in Part A will be used for baseline values in Part B.

Time frame:
From baseline up to 52 weeks after first dose in Part B
Reported as:
Count of participants · Participants
The Number of Participants With Abnormal Laboratory Parameters of Clinical Significance in the Blinded Treatment Period (Part B)
ParticipantsOpen Label MMF + BMS-986165
The Number of Participants With Abnormal Laboratory Parameters of Clinical Significance in the Blinded Treatment Period (Part B)0
PrimaryPercent Change From Baseline in 24-hour Urine Protein:Creatinine Ratio (UPCR) at Week 24 in the Blinded Treatment Period (Part B)

The percent change from baseline in UPCR based on 24-hour urine collections. 24-hour urine specimens measure the levels of proteins and creatinine in urine and will be used for the UPCR at baseline (week 12) and week 24.

Time frame:
Week 24
Reported as:
Number · Percent change from baseline
Percent Change From Baseline in 24-hour Urine Protein:Creatinine Ratio (UPCR) at Week 24 in the Blinded Treatment Period (Part B)
Percent change from baselineOpen Label MMF + BMS-986165
Percent Change From Baseline in 24-hour Urine Protein:Creatinine Ratio (UPCR) at Week 24 in the Blinded Treatment Period (Part B)-34.86
SecondaryThe Number of Participants With Partial Renal Response (PRR) at Week 24 in the Blinded Treatment Period (Part B)

The number of participants with partial renal response (PRR) defined as ≥ 50% reduction from baseline in 24-hour Urine Protein:Creatinine Ratio (UPCR). 24-hour urine specimens measure the levels of proteins and creatinine in urine and will be used for the UPCR at baseline (week 12) and week 24.

Time frame:
Week 24
Reported as:
Count of participants · Participants
The Number of Participants With Partial Renal Response (PRR) at Week 24 in the Blinded Treatment Period (Part B)
ParticipantsOpen Label MMF + BMS-986165
The Number of Participants With Partial Renal Response (PRR) at Week 24 in the Blinded Treatment Period (Part B)0
SecondaryThe Number of Participants With Partial Renal Response (PRR) at Week 52 in the Blinded Treatment Period (Part B)

The number of participants with partial renal response (PRR) defined as ≥ 50% reduction from baseline in 24-hour Urine Protein:Creatinine Ratio (UPCR). 24-hour urine specimens measure the levels of proteins and creatinine in urine and will be used for the UPCR at baseline (week 12) and week 52.

Time frame:
Week 52
Reported as:
Count of participants · Participants
The Number of Participants With Partial Renal Response (PRR) at Week 52 in the Blinded Treatment Period (Part B)
ParticipantsOpen Label MMF + BMS-986165
The Number of Participants With Partial Renal Response (PRR) at Week 52 in the Blinded Treatment Period (Part B)0
SecondaryThe Number of Participants With Complete Renal Response (CRR) at Week 24 in the Blinded Treatment Period (Part B)

The number of participants with complete renal response (CRR) defined as a 24-hour Urine Protein:Creatinine Ratio (UPCR) ≤ 0.5 mg/mg and an estimated glomerular filtration rate (eGFR) (using the MDRD equation) ≥ 60 mL/min or ≤ 20% decrease from baseline.

Time frame:
Week 24
Reported as:
Count of participants · Participants
The Number of Participants With Complete Renal Response (CRR) at Week 24 in the Blinded Treatment Period (Part B)
ParticipantsOpen Label MMF + BMS-986165
The Number of Participants With Complete Renal Response (CRR) at Week 24 in the Blinded Treatment Period (Part B)0
SecondaryThe Number of Participants With Complete Renal Response (CRR) at Week 52 in the Blinded Treatment Period (Part B)

The number of participants with complete renal response (CRR) defined as a 24-hour Urine Protein:Creatinine Ratio (UPCR) ≤ 0.5 mg/mg and an estimated glomerular filtration rate (eGFR) (using the MDRD equation) ≥ 60 mL/min or ≤ 20% decrease from baseline.

Time frame:
Week 52
Reported as:
Count of participants · Participants
The Number of Participants With Complete Renal Response (CRR) at Week 52 in the Blinded Treatment Period (Part B)
ParticipantsOpen Label MMF + BMS-986165
The Number of Participants With Complete Renal Response (CRR) at Week 52 in the Blinded Treatment Period (Part B)0
SecondaryThe Number of Participants With Complete Renal Response (CRR) Plus Successful Corticosteroid Taper to ≤ 7.5 mg/Day at Week 24 in the Blinded Treatment Period (Part B)

The number of participants with complete renal response (CRR) defined as a 24-hour Urine Protein:Creatinine Ratio (UPCR) ≤ 0.5 mg/mg and an estimated glomerular filtration rate (eGFR) (using the MDRD equation) ≥ 60 mL/min or ≤ 20% decrease from baseline who was also able to successfully taper corticosteroid use to ≤ 7.5 mg/day.

Time frame:
Week 24
Reported as:
Count of participants · Participants
The Number of Participants With Complete Renal Response (CRR) Plus Successful Corticosteroid Taper to ≤ 7.5 mg/Day at Week 24 in the Blinded Treatment Period (Part B)
ParticipantsOpen Label MMF + BMS-986165
The Number of Participants With Complete Renal Response (CRR) Plus Successful Corticosteroid Taper to ≤ 7.5 mg/Day at Week 24 in the Blinded Treatment Period (Part B)0
SecondaryThe Number of Participants With Complete Renal Response (CRR) Plus Successful Corticosteroid Taper to ≤ 7.5 mg/Day at Week 52 in the Blinded Treatment Period (Part B)

The number of participants with complete renal response (CRR) defined as a 24-hour Urine Protein:Creatinine Ratio (UPCR) ≤ 0.5 mg/mg and an estimated glomerular filtration rate (eGFR) (using the MDRD equation) ≥ 60 mL/min or ≤ 20% decrease from baseline who was also able to successfully taper corticosteroid use to ≤ 7.5 mg/day.

Time frame:
Week 52
Reported as:
Count of participants · Participants
The Number of Participants With Complete Renal Response (CRR) Plus Successful Corticosteroid Taper to ≤ 7.5 mg/Day at Week 52 in the Blinded Treatment Period (Part B)
ParticipantsOpen Label MMF + BMS-986165
The Number of Participants With Complete Renal Response (CRR) Plus Successful Corticosteroid Taper to ≤ 7.5 mg/Day at Week 52 in the Blinded Treatment Period (Part B)0

Adverse events

Collected over All-cause mortality was assessed from first dose to study completion (up to approximately 26 months). SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 16 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label MMF0/16 (0%)1/16 (6.3%)7/16 (43.8%)
Open Label MMF + BMS-9861650/1 (0%)1/1 (100%)1/1 (100%)
Most frequent serious events
Most frequent serious events
EventOpen Label MMFOpen Label MMF + BMS-986165
COVID-19 pneumoniaInfections and infestations1/161/1
Most frequent other events
Showing 10 of 19
Most frequent other events
EventOpen Label MMFOpen Label MMF + BMS-986165
Activated partial thromboplastin time prolongedInvestigations0/161/1
International normalised ratio increasedInvestigations0/161/1
Prothrombin time prolongedInvestigations0/161/1
Flank painMusculoskeletal and connective tissue disorders0/161/1
Deafness neurosensoryEar and labyrinth disorders1/160/1
Abdominal discomfortGastrointestinal disorders1/160/1
Abdominal distensionGastrointestinal disorders1/160/1
HaematocheziaGastrointestinal disorders1/160/1
PyrexiaGeneral disorders1/160/1
Gallbladder polypHepatobiliary disorders1/160/1

Baseline characteristics

Baseline analysis population for Open Label MMF includes all participants that did not meet randomization criteria in Part B. Open Label MMF + BMS-986165 includes the participant that met the randomization criteria in Part B.

Age, Categorical
Age, Categorical(Participants)Open Label MMFOpen Label MMF + BMS-986165Total
<=18 years000
Between 18 and 65 years15116
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Open Label MMFOpen Label MMF + BMS-986165Total
Female10010
Male516
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Open Label MMFOpen Label MMF + BMS-986165Total
Hispanic or Latino516
Not Hispanic or Latino909
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open Label MMFOpen Label MMF + BMS-986165Total
American Indian or Alaska Native000
Asian505
Native Hawaiian or Other Pacific Islander000
Black or African American303
White516
More than one race000
Unknown or Not Reported202
08

Study locations

100 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
  • The Nephrology Group
    Fresno, California 93720, United States
  • The Regents of The University of California
    Los Angeles, California 90095, United States
  • University of Colorado School of Medicine
    Aurora, Colorado 80045, United States
  • Local Institution - 0029
    Gainesville, Florida 32603, United States
  • Emory University
    Atlanta, Georgia 30303, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Atlanta Nephrology Referral Center
    Lawrenceville, Georgia 30046, United States
  • Northwestern Medical Faculty Foundation
    Chicago, Illinois 60611-5966, United States
  • The University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • Nephrology Associates of Northern Illinois and Indiana - Fort Wayne
    Fort Wayne, Indiana 46804, United States
  • Johns Hopkins University, Office of Research Administration
    Baltimore, Maryland 21205, United States
  • Renal and Transplant Associates of New England, PC
    Springfield, Massachusetts 01107, United States
  • Brighton Center for Specialty Care
    Brighton, Michigan 48116, United States
  • Clinical Research Consultants - Kansas City
    Kansas City, Missouri 64111, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Rutgers New Jersey Medical School
    Newark, New Jersey 07103, United States
  • Institute for Rheumatic and Autoimmune Diseases
    Summit, New Jersey 07901, United States
  • NewYork-Presbyterian Queens
    Fresh Meadows, New York 11365, United States
  • Northwell Health Physician Partners at Great Neck
    Great Neck, New York 11021, United States
  • Local Institution - 0039
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • State University of New York Upstate Medical University
    Syracuse, New York 13210-2342, United States
  • East Carolina University Physicians
    Greenville, North Carolina 27834, United States
  • Ohio State University, Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Local Institution - 0066
    Oklahoma City, Oklahoma 73104, United States
  • Northeast Clinical Research Center
    Bethlehem, Pennsylvania 18017, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Local Institution - 0030
    Charleston, South Carolina 29425, United States
  • Office of Ramesh C. Gupta, MD
    Memphis, Tennessee 38119, United States
  • Nephrotex Research Group
    Dallas, Texas 75231, United States
  • Dallas Nephrology Associates - North Office
    Dallas, Texas 75240, United States
  • El Paso Medical Research Institute
    El Paso, Texas 79902, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • University of Washington School of Medicine
    Seattle, Washington 98195-6340, United States
  • Liverpool Hospital
    Liverpool, New South Wales 1871, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Universitair Ziekenhuis Leuven
    Leuven, 3000, Belgium
  • Centre Hospitalier Universitaire de Liege Site Sart Tilman
    Liege, 4000, Belgium
  • Sheldon M. Chumir Health Center
    Calgary, Alberta T2N 4Z6, Canada
  • Toronto Western Hospital
    Toronto, Ontario M5T 3A9, Canada
  • Centre Hospitalier Universitaire de Quebec Hospital Centre Hospitalier de IUniversite Laval
    Quebec, G1V 3M7, Canada
  • Local Institution
    Guangzhou, Guangdong 510080, China
  • Local Institution
    Xian, Shan3xi 710061, China
  • Revmatologicky Ustav
    Praha 2, 12850, Czechia
  • Vseobecna Fakultni Nemocnice v Praze
    Praha, 128 08, Czechia
  • Universitaetsklinikum Essen
    Essen, 45147, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitatsmedizin der Johannes Gutenberg Universitat Mainz
    Mainz, 55131, Germany
  • Local Institution
    Haifa, 3339419, Israel
  • Local Institution
    Kfar Saba, 4428164, Israel
  • Local Institution
    Tel Aviv, 6423906, Israel
  • Local Institution - 0082
    Milano, 20132, Italy
  • Azienda SocioSanitaria Territoriale Fatebenefratelli Sacco
    Milan, 20157, Italy
  • Universita degli Studi di Napoli Federico II
    Napo, 80131, Italy
  • Istituto Scientifico di Pavia
    Pavia, 27100, Italy
  • Local Institution
    Busan, 602-715, Korea, Republic of
  • Local Institution - 0071
    Daejeon, 35015, Korea, Republic of
  • Local Institution - 0090
    Gwangju, 61469, Korea, Republic of
  • Local Institution - 0056
    Seoul, 03080, Korea, Republic of
  • Local Institution
    Seoul, 05030, Korea, Republic of
  • Local Institution
    Seoul, 05505, Korea, Republic of
  • Local Institution
    Seoul, 137-701, Korea, Republic of
  • Local Institution
    Suwon, 442-723, Korea, Republic of
  • Unidad de Investigacion de las Enfermedades Reumaticas
    Ciudad de Mexico, Distrito Federal 06090, Mexico
  • Local Institution - 0094
    Mexico, Distrito Federal 11850, Mexico
  • Morales Vargas Centro de Investigacion
    Leon, Guanajuato 37000, Mexico
  • Centro Integral de Reumatologia
    Guadalajara, Jalisco 44160, Mexico
  • Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.
    Zapopan, Jalisco 45030, Mexico
  • Servicios Hospitalarios de Mexico
    Chihuahua, 31217, Mexico
  • Centro de Atencion e Investigacion Cardiovascular del Potosi
    San Luis Potosi, 78200, Mexico
  • Hospital Central Doctor Ignacio Morones Prieto
    San Luis Potosi, 78240, Mexico
  • Maastricht University Medical Centre
    Maastricht, 6229 HX, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 GD, Netherlands
  • Medical Center
    Kemerovo, 650070, Russian Federation
  • City Clinical Hospital #15 named after O.M. Filatova
    Moscow, 111539, Russian Federation
  • V.A. Nasonova Research Rheumatology Institute
    Moscow, 115522, Russian Federation
  • Local Institution - 0015
    Saratov, 410053, Russian Federation
  • Fundacio Puigvert
    Barcelona, 08025, Spain
  • Hospital Universitari Vall dHebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Regional Universitario de Malaga Hospital General
    Malaga, 29010, Spain
  • Hospital Universitario Nuestra Senora de Valme
    Sevilla, 41014, Spain
  • Local Institution
    Hualien, 97002, Taiwan
  • Local Institution
    Kaohsiung City, 833, Taiwan
  • Local Institution
    Taichung, 40705, Taiwan
  • Local Institution - 0037
    Tainan, 71004, Taiwan
  • Local Institution
    Taipei, 112, Taiwan
  • Brighton and Sussex University Hospitals NHS Trust
    Brighton, BN2 5BE, United Kingdom
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge, CB2 2QQ, United Kingdom
  • University Hospitals of Leicester NHS Trust
    Leicester, LE5 4PW, United Kingdom
  • Barts Health NHS Trust
    London, E1 1BB, United Kingdom
  • Manchester University NHS Foundation Trust
    Manchester, M13 9WL, United Kingdom
  • Epsom and Saint Helier University Hospitals NHS Trust
    Surrey, SM5 1AA, United Kingdom
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Oct 2020, 15 months.

Results were first posted in Oct 2022, 1 year 11 months after primary completion. A results delay was requested in Oct 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2019
First posted
May 9, 2019
StartActual
Jul 15, 2019
Primary completionActual
Oct 29, 2020
CompletionActual
Sep 17, 2021
Results delay requested
Oct 28, 2021
Results first posted
Oct 17, 2022
Last update
Oct 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03943147
Responsible party
Sponsor
First posted
May 9, 2019
Start date
Jul 15, 2019
Primary completion
Oct 29, 2020
Completion
Sep 17, 2021
Results posted
Oct 17, 2022
Last update
Oct 17, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion